For testing the HGF/HGFL protease inhibitors, we initially chose the CRC cell lines SC and CC-CR that exhibit de novo and acquired modes of cetuximab resistance, respectively, and both have elevated MET and RON phosphorylation levels and respond to the MET/RON inhibitor crizotinib [10–12]. The gene discussed is MET; the disease is colorectal carcinoma.